These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Aldosterone as a Possible Contributor to Eye Diseases. Higashide T; Hirooka K; Kometani M; Sugiyama K Endocrinology; 2022 Dec; 164(2):. PubMed ID: 36461718 [TBL] [Abstract][Full Text] [Related]
7. Clinical Features of Pregnancy-associated Retinal and Choroidal Diseases Causing Acute Visual Disturbance. Park YJ; Park KH; Woo SJ Korean J Ophthalmol; 2017 Aug; 31(4):320-327. PubMed ID: 28752697 [TBL] [Abstract][Full Text] [Related]
8. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Campochiaro PA; Akhlaq A Prog Retin Eye Res; 2021 Jul; 83():100921. PubMed ID: 33248215 [TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516 [TBL] [Abstract][Full Text] [Related]
10. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Fletcher EL; Phipps JA; Ward MM; Vessey KA; Wilkinson-Berka JL Prog Retin Eye Res; 2010 Jul; 29(4):284-311. PubMed ID: 20380890 [TBL] [Abstract][Full Text] [Related]
11. Retinal vasculopathy is reduced by dietary salt restriction: involvement of Glia, ENaCα, and the renin-angiotensin-aldosterone system. Deliyanti D; Armani R; Casely D; Figgett WA; Agrotis A; Wilkinson-Berka JL Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2033-41. PubMed ID: 25012132 [TBL] [Abstract][Full Text] [Related]
12. Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. Sha L; Zhao Y; Li S; Wei D; Tao Y; Wang Y J Transl Med; 2024 Oct; 22(1):898. PubMed ID: 39367441 [TBL] [Abstract][Full Text] [Related]
13. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Vinores SA; Youssri AI; Luna JD; Chen YS; Bhargave S; Vinores MA; Schoenfeld CL; Peng B; Chan CC; LaRochelle W; Green WR; Campochiaro PA Histol Histopathol; 1997 Jan; 12(1):99-109. PubMed ID: 9046048 [TBL] [Abstract][Full Text] [Related]
14. [Pathophysiology of macular diseases--morphology and function]. Iida T Nippon Ganka Gakkai Zasshi; 2011 Mar; 115(3):238-74; discussion 275. PubMed ID: 21476310 [TBL] [Abstract][Full Text] [Related]
15. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. Smith RO; Ninchoji T; Gordon E; André H; Dejana E; Vestweber D; Kvanta A; Claesson-Welsh L Elife; 2020 Apr; 9():. PubMed ID: 32312382 [TBL] [Abstract][Full Text] [Related]
16. Aldosterone Exposure Causes Increased Retinal Edema and Severe Retinopathy Following Laser-Induced Retinal Vein Occlusion in Mice. Allingham MJ; Tserentsoodol N; Saloupis P; Mettu PS; Cousins SW Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3355-3365. PubMed ID: 30025072 [TBL] [Abstract][Full Text] [Related]
17. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Ou WC; Brown DM; Payne JF; Wykoff CC Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848 [TBL] [Abstract][Full Text] [Related]
18. Does laser still have a role in the management of retinal vascular and neovascular diseases? Shah AM; Bressler NM; Jampol LM Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309 [TBL] [Abstract][Full Text] [Related]
19. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial. Dupas B; Castro-Farias D; Girmens JF; Eginay A; Couturier A; Villeroy F; Delyfer MN; Creuzot-Garcher C; Giocanti-Auregan A; Béral L; Arndt C; Mesnard C; Vicaut E; Chaumet-Riffaud P; Durand-Zaleski I; Paques M Trials; 2024 Apr; 25(1):273. PubMed ID: 38649937 [TBL] [Abstract][Full Text] [Related]
20. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]